Pulsesight therapeutics announces first close of its series a financing to fund clinical development of pst-611 in dry amd

Paris, feb. 13, 2025 (globe newswire) -- pulsesight therapeutics sas, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its series a financing with existing investor pureos bioventures committing new funds to support the phase i study of pst-611 and enable preparation for a phase iia clinical trial.
AMD Ratings Summary
Quant
AMD Quant Ranking
Sector
Industry
Quant Rating
Quant Score